The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10B | Lipid modifying agents, combinations | |
| 4 | C10BA | Combinations of various lipid modifying agents | |
| 5 | C10BA04 | Simvastatin and fenofibrate |
| Active Ingredient | Description | |
|---|---|---|
| Simvastatin and Fenofibrate |
The effects of simvastatin and fenofibrate are complementary. Simvastatin has a potent activity in inhibiting HMG-CoA reductase, an enzyme that catalyses the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthesis of cholesterol. Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type alpha (PPARα). Through activation of PPARα, fenofibrate activates lipoprotein lipase production and reduces production of apoprotein CIII. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CHOLIB Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
